Company: FTII
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0001641172-25-023249
Chunk: 2

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-12
Form: 8-K
Item: Item 1.01
Chunk 2
---
 (xiv) licenses and permits, (xv) compliance with laws, (xvi)
governmental approvals, (xvii) benefit plans, (xviii) affiliate transactions, (xix) finders and brokers, and (xx) insurance. The representations
and warranties of the parties contained in the Merger Agreement will terminate and be of no further force and effect as of the Closing.

Covenants

The
Merger Agreement contains customary covenants of the parties with respect to the conduct of the Company, Longevity and Merger Sub during
the period between the execution of the Merger Agreement and the Closing, including (i) the operation of business in the ordinary course
of business prior to the consummation of the Transactions, (ii) the parties’ efforts to satisfy conditions to consummation of the
Transactions, (iii) prohibitions on engaging in discussions regarding alternative transactions, (iv) the preparation and filing of a
registration statement on Form S-4 (the “ Registration Statement Securities Act Company Stockholder Matters

   3  

Closing
Conditions

The
consummation of the Transactions is subject to customary closing conditions for transactions involving special purpose acquisition companies,
including, among others: (i) approval of the Company Stockholder Matters by the Company’s stockholders (the “ Required
Company Stockholder Approval

Additionally,
the obligations of the Company and Merger Sub to consummate the Transactions are also conditioned upon, among others, the closing of
the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue, LLC pursuant to each of the Cerevast Acquisition
Agreement and the Aegeria Acquisition Agreement (as each is defined in the Merger Agreement and together, the “ Target Acquisitions

The
obligation of the Company to consummate the Business Combination is also subject to the satisfaction or waiver of certain other closing
conditions, including, among others, the absence of a Material Adverse Effect (as defined in the Merger Agreement) with respect to Longevity,
Cerevast Medical, Inc., and Aegeria Soft Tissue, LLC since the date of the Merger Agreement that is continuing.

Termination

The
Merger Agreement may be terminated as follows:

  i.        by                                                                                                
  ii.       by                                                                                                
  iii.      by                                                                                                
  iv.       by                                                                                                

   4  

  v.         by                                                                                                
  vi